Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Corticosteroid Pulses for Moderate Flares of Ulcerative Colitis
NCT02921555Phase 4Terminated
- Sponsor
- GETECCU
- Start
- Oct 2018
- Primary completion
- Nov 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone injection in ulcerative colitis (UC) (2 arms), sponsored by GETECCU. Primary endpoint: Percentage of Participants With Endoscopic and Clinical Remission at 8 weeks. Started Oct 2018; status: terminated.
02
Drugs
methylprednisolone injection
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02921555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921555.